Indaptus Therapeutics Inc (INDP)

US · Healthcare · Biotechnology

$3.93+22.43%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-1.8M

EPS

$-0.02

Market cap

$369.1M

Forward P/E

0.0

P/B

32.10

Book value

$0.09

EPS (TTM)

$-3.56

52-week high

$5.96

52-week low

$0.92

50-day MA

$1.78

200-day MA

$2.19

Beta

1.17

Analysts rate Indaptus Therapeutics Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $10.00.

Insiders

82.45%

Institutions

0.30%

Fund	Stake
Geode Capital Management, LLC	1.25%
Millennium Management LLC	0.53%
Morgan Stanley - Brokerage Accounts	0.12%
Tower Research Capital LLC	0.09%
SBI Securities Co Ltd	0.00%
CWM, LLC duplicate	0.00%
Bank of America Corp	0.00%
Citadel Advisors Llc	0.00%

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Indaptus Therapeutics Inc — free to start.

Data updated 2026-09-18.